Genprex (GNPX) Income from Continuing Operations (2016 - 2025)
Genprex (GNPX) posted quarterly Income from Continuing Operations of 693150.0 for Q1 2025, up 88.46% year-over-year from 367797.27 in Q1 2024, and up 83.59% quarter-over-quarter from 4225159.0 in Q4 2024.
Genprex (GNPX) Income from Continuing Operations (2016 - 2025) Analysis & Trends
Genprex's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 693150.0 for Q1 2025.
- In Q1 2025, Income from Continuing Operations rose 88.46% year-over-year to 693150.0; the TTM figure through Mar 2025 stood at 15797351.0 (up 43.03% YoY), while the FY2025 annual figure was 46115619.0, up 5.33% from the prior year.
- Income from Continuing Operations for Q1 2025 stood at 693150.0, up from 4225159.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 693150.0 in Q1 2025, with the low at 9259131.0 in Q1 2023.
- The 5-year median for Income from Continuing Operations is 5949307.0 (2023), against an average of 5651962.76.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations slumped 79.42% in 2022, then jumped 88.46% in 2025.
- Genprex's Income from Continuing Operations stood at 6751273.0 in 2021, then gained by 3.03% to 6546498.0 in 2022, then rose by 9.12% to 5949307.0 in 2023, then gained by 28.98% to 4225159.0 in 2024, then jumped by 83.59% to 693150.0 in 2025.
- Business Quant data shows GNPX's Income from Continuing Operations at 693150.0 in Q1 2025, 4225159.0 in Q4 2024, and 4347288.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -693,150.00 |
| Dec 31, 2024 | -4.23 Mn |
| Sep 30, 2024 | -4.35 Mn |
| Jun 30, 2024 | -6.53 Mn |
| Mar 31, 2024 | -6.01 Mn |
| Dec 31, 2023 | -5.95 Mn |
| Sep 30, 2023 | -7.76 Mn |
| Jun 30, 2023 | -8.01 Mn |
| Mar 31, 2023 | -9.26 Mn |
| Dec 31, 2022 | -6.55 Mn |
| Sep 30, 2022 | -6.17 Mn |
| Jun 30, 2022 | -5.79 Mn |
| Mar 31, 2022 | -5.31 Mn |
| Dec 31, 2021 | -6.75 Mn |
| Sep 30, 2021 | -3.44 Mn |
| Jun 30, 2021 | -3.99 Mn |
| Mar 31, 2021 | -5.31 Mn |
| Dec 31, 2020 | -5.23 Mn |
| Sep 30, 2020 | -2.77 Mn |
| Jun 30, 2020 | -4.37 Mn |